GLP-1 Receptor Agonists and SGLT2 Inhibitors Reduce Liver-Related Risks and HCC in Type 2 Diabetes: Study
South Korea: A systematic review and meta-analysis published in Hepatology has revealed that GLP-1 receptor agonists and SGLT2 inhibitors are associated with lower risks of liver-related events and hepatocellular carcinoma…
